Fragment-Based Deconstruction of Bcl-x L Inhibitors
Citations Over TimeTop 10% of 2010 papers
Abstract
Fragment-based drug design consists of screening low-molecular-weight compounds in order to identify low-affinity ligands that are then modified or linked to yield potent inhibitors. The method thus attempts to build bioactive molecules in a modular way and relies on the hypothesis that the fragment binding mode will be conserved upon elaboration of the active molecule. If the inverse process is considered, do the fragments resulting from the deconstruction of high-affinity inhibitors recapitulate their binding mode in the large molecule? Few studies deal with this issue. Here, we report the analysis of 22 fragments resulting from the dissection of 9 inhibitors of the antiapoptotic protein Bcl-x(L). To determine if the fragments retained affinity toward the protein and identify their binding site, ligand-observed and protein-observed NMR experiments were used. The analysis of the fragments behavior illustrates the complexity of low-affinity protein-ligand interactions involved in the fragment-based construction of bioactive molecules.
Related Papers
- → Protein–protein interactions as targets for small-molecule therapeutics in cancer(2008)119 cited
- → A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors(2002)116 cited
- → Structural Properties of Non-Traditional Drug Targets Present New Challenges for Virtual Screening(2013)38 cited
- → Mimicking Intermolecular Interactions of Tight Protein–Protein Complexes for Small‐Molecule Antagonists(2017)15 cited
- Mimicking Intermolecular Interactions of Tight Protein–Protein Complexes for Small-Molecule Antagonists(2017)